Bristol-Myers Squibb Company (OTCMKTS:BMYMP) Files An 8-K Other Events

Bristol-Myers Squibb Company (OTCMKTS:BMYMP) Files An 8-K Other Events

Story continues below

ITEM 8.01.

OTHER EVENTS
On June 14, 2017, Bristol-Myers Squibb Company (the Company)
issued a press release announcing the commencement of a cash
tender offer to purchase any and all of its outstanding 5.875%
Notes due 2036, 6.125% Notes due 2038 and 6.875% Debentures due
2097 (the Notes), on the terms and subject to the conditions
set forth in the Offer to Purchase, dated June 14, 2017, and
the related Letter of Transmittal.
A copy of the press release announcing the commencement of the
tender offer is attached as Exhibit 99.1 to this Current Report
on Form 8-K.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
Exhibit No.
Description
99.1
June 14, 2017 press release entitled Bristol-Myers Squibb
Announces Cash Tender Offer For Any and All of Certain of
Its Outstanding Debt Securities.


About Bristol-Myers Squibb Company (OTCMKTS:BMYMP)

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

An ad to help with our costs